Innovating Works

EUROPEAN SOCIETY FOR BLOOD AND MARROW TR...

Desconocido
T2EVOLVE: Accelerating Development and Improving Access to CAR and TCR engineered T cell therapy EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION participó en un H2020: H2020-JTI-IMI2-2019-18-two-stage Immune cells that are empowered by gene-engineering to seek and destroy cancer cells (engineered T cell therapy) constitute a transformative...
2020-11-24 - 2025-12-31 | Financiado
HARMONY PLUS: HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINES OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY PLUS EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION participó en un H2020: H2020-JTI-IMI2-2019-19-single-stage Haematological malignancies (HM), also known as blood cancers, are a heterogeneous and complex group of multicausal diseases that can’t be e...
2020-05-26 - 2024-03-31 | Financiado
HARMONY: Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY Sofia ref.... EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION participó en un H2020: H2020-JTI-IMI2-2015-06-two-stage Despite significant recent progress in the field of hematological malignancies (HMs), with increasing survival rates and improvement in qual...
2016-12-22 - 2023-06-30 | Financiado
CELL-PID: Advanced Cell based Therapies for the treatment of Primary ImmunoDeficiency EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION participó en un FP7: Primary immune deficiencies (PID) are inherited disorders of the adaptive and innate immune system marked by severe infections, autoimmunity...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.